Coronavirus Stocks To Watch: Medical Leader Baxter Falls From New Buy Point Investor’s Business Daily

Industrial companies in particular continue to see record backlogs, with the easing of logistics and supply chain constraints only just starting to have an impact on deliveries and lead times. In this article, we discuss 11 best COVID stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best COVID Stocks To Buy According To Hedge Funds. This week’s headlines almost sound like the plot of a thriller movie. A Chinese city that’s home to 11 million people is locked down, with no one allowed to enter or leave after a deadly virus infects hundreds and kills at least 26 people.

Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns. The Chinese discount retailer bolted past a 15.07 buy point on earnings in a double bottom on March 5. The stock has managed to hold those gains despite the coronavirus impact on China and international markets. Vipshop has posted two straight quarters of triple-digit earnings growth. So while now is a challenging time for investors, know that the market will eventually turn around. While we wait for that to happen, be sure to (1) take action to protect your capital, (2) keep your watchlist up to date, and (3) stay grounded.

  • While there is a lot of overlap between biotech and pharma, there are some key differences.
  • Aside from the COVID-19 vaccine, the company’s lead drug candidate is an experimental mRNA therapy targeting melanoma and other solid tumors.
  • He purchased over 460,000 shares at an average price of roughly $1.83.
  • The study consisted of only 251 people; weeks earlier RedHill had said the drug failed to show an effect in a broader group of patients.
  • But one sector, in particular, could profit from the outbreak.
  • First, on this list of penny stocks, Algernon Pharmaceuticals Inc. (AGNPF Free Report) (AGN) has caught more attention this week after a big update on Monday.

They should stop buying stocks, aside from exceptional breakouts in exceptional stocks, such as those in the IBD 50. The names below are among the best stocks to buy or watch now. KeyBanc also raises its price target on Club holding Alphabet (GOOGL) to $155 a share, up from $145, while maintaining an overweight rating on shares. The firm notes a slight improvement in the ad market moving into the fourth quarter, along with strength in retail and e-commerce. The FANG stock is testing resistance as it tries to find support at its 10-week moving average line.

Over the last three years, Veeva has generated average annual earnings growth of 46%. Rather than advance just one candidate, Pfizer and the German company BioNTech are working together to test four related vaccine candidates. The different candidates within the BNT162 program deliver strands of messenger RNA (mRNA) that cause human cells to produce slightly different portions of SARS-CoV-2. On your list of companies with experimental new drugs to watch, these should be at the very top. Baxter stock is trading just under a 95.10 buy point in a cup base after Tuesday’s sharp losses, according to MarketSmith chart analysis.

In particular, Moderna (MRNA -2.46%) and Regeneron (REGN 0.14%) should be winning investments over the next year. Moderna’s coronavirus vaccine will provide the company with recurring revenues and earnings for the first time in its history. And Regeneron’s monoclonal antibody cocktail treatments for COVID-19 should bolster its already-formidable bottom line.

IBD Newsletters

The biotech company is developing a vaccine to be administered orally. It takes the form of a tablet — just like many everyday medicines. Second, healthcare systems would save money on transport and storage because the tablet is stable at room temperature; traditional vaccines require refrigeration. Since ChAdOx1 MERS had already passed a phase 1 safety study with flying colors, regulators were quick to allow clinical trials with AZD1222. With the stock market outlook in a correction — according to the IBD Big Picture — investors should avoid any buying of stocks and instead be focusing on finding the top growth ideas in a weak environment. The new base is a first-stage formation, which works in the stock’s favor.

Wolfe Research downgrades Netflix (NFLX) to a neutral-equivalent rating, from outperform, without a price target. Lululemon Athletica’s stock will join the S&P 500 effective Oct. 18. The excercise apparel company will replace Activision Blizzard, which was acquired by Microsoft on Friday. Shares of AKRX stock exploded at the open breaking quickly above $0.30. While there hasn’t been any news to speak of, the market is racing today. Remdesivir is showing “rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week” in patients at a Chicago hospital.

  • Also learn about any issues the vaccine makers have experienced.
  • The company topped estimates with a 32% earnings jump to $2.98 per share.
  • While some traders might argue that they are exclusive to the Over-The-Counter or “OTC exchange,” the truth is that numerous low-priced stocks can also be found on larger exchanges.
  • Following a business update on the 15th, it seemed that there were more questions than answers.
  • The FANG stock is testing resistance as it tries to find support at its 10-week moving average line.
  • Moderna also has 15 other candidates in clinical trials and plans to heavily invest in expanding its pipeline.

They could be potential leaders of a new stock market uptrend. Some of these companies are working on COVID treatments and vaccines while others see a huge demand of their products and services during lockdowns caused by COVID-19 outbreaks and other pandemics. Veeva Systems (VEEV) has emerged as one of the leading coronavirus stocks to watch. The cloud-based life sciences software leader is working with several pharma and biotech companies leading the development of coronavirus vaccines and treatments.

Invest Smarter with The Motley Fool

Regeneron plans to produce in the neighborhood of 100,000 doses in January, and has set a target for production capacity of 2 million doses per year. It previously signed a $450 million deal with the U.S. government to supply enough doses to treat about 300,000 patients. So if it sells additional doses at that price, the antibody cocktail could bring in $3 billion per year for Regeneron. That would be a large sum to add to its current revenues of $9.24 billion.

Zscaler Stock

Staar Surgical is still forming a new base cup with a 42.83 buy point. The RS line continues to strengthen, hitting a new high Monday. Quidel stock is about 6% off its 52-week high after hitting a new high on April 17. Edwards Lifesciences is moving up the right side of a choppy cup base. For now, the buy point is 247.74, but be on the lookout for a potential handle to offer a more risk-optimal entry. In afternoon trading Tuesday, the medical stock leader fell more than 3% to move further from its recent buy point.

Join Over Half a Million Premium Members Receiving…

And wild stock market swings have investors questioning how to handle stocks on the IBD Breakout Stocks Index, such as Netflix (NFLX), ZTO Express (ZTO), and New Oriental Education & Technology (EDU). On Friday it all came to a head with popular a short reporter released their opinion on the company. Hindenburg Research explained that it believed what is price action the news to be “bogus” and cited a “checkered past” from its CEO. SCWorx released news on Monday that it received a committed purchase order from Rethink My Healthcare, a U.S. -based virtual healthcare network. This was for two million COVID-19 Rapid Testing Units, “with provision for additional weekly orders of 2 million units for 23 weeks/.

As if all that wasn’t enough, Arista Networks is a member of the prestigious IBD Leaderboard list of top stocks. Analysts expect explosive profit growth of 194% in fiscal 2024 and 62% in 2025. The Russian invasion of Ukraine continues to cast a shadow over markets while the Israel-Hamas war adds more uncertainty. Get this delivered to your inbox, and more info about our products and services.

Struggling with its COVID-19 vaccine isn’t a critical blow to AstraZeneca. The drug company’s lineup includes several products with strong sales growth, pepperstone canada especially its cancer drugs Imfinzi and Lynparza. Its drug pipeline is also well-developed and features a large number of late-stage candidates.

This continues the list in our article Best Penny Stocks To Buy? Also based in China, ZTO Express have been bucking the market downturn and continuing to rise, with its RS line trending the tools for forex trading sharply higher. The 2016 IPO stock is now trading right around a new all-time high. ZTO Express is scheduled to report Q4 and full 2019 earnings on Monday, after the market close.

While Akorn is a specialty pharmaceutical company, there haven’t been many new headlines about its path toward or away from COVID-19 treatments. And after missing on its last quarterly earnings, the future prospects weren’t all that bright for Akorn either. In fact, there were even FORM 4 filings showing insiders selling stock in larger amounts.

The stock also earns a 98 Composite Rating, meaning it’s outpacing 98% of all stocks in terms of the most important stock-picking traits. The cloud play also made IBD’s latest list of new buys by the best mutual funds. With a strong earnings stability rating of 5 (the lower the number, the more stable the earnings), VEEV stock has now earned a spot on the watchlist for IBD Long-Term Leaders. In June, Regeneron began clinical trials for REGN-COV2 as a treatment, and in July as a preventative measure. Investors can use the Composite Rating to easily measure a stock’s main fundamental, technical and fund ownership metrics vs. other stocks.

But management hasn’t publicly committed to any pricing scheme yet, so the actual figures could wind up dramatically different. This year, Regeneron made headlines when doctors gave the company’s experimental antibody cocktail to President Trump after he contracted COVID-19. Though the cocktail is not authorized for use in people on oxygen or those who have been hospitalized for coronavirus, the hope is that it could prevent hospitalizations in the first place. Pfizer said it would reverse $4.2 billion in revenue after revising its agreement with the U.S. government related to its Covid-19 treatment Paxlovid. The company agreed to take back unused courses for the oral anti-viral pill as it seeks to roll out its commercial version of the drug. Algernon has filed new intellectual property rights globally for Ifenprodil for the treatment of respiratory diseases.